Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer

Prostate cancer is a highly heterogeneous disease. Progression on androgen deprivation therapy (ADT) to castration-resistant (CRPC), or neuroendocrine prostate cancer (NEPC), is associated with poor patient survival. This comment highlights recent evidence on the epigenetic mechanisms underlying the...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 14; no. 1; p. 567
Main Authors Chakraborty, Goutam, Gupta, Kasmira, Kyprianou, Natasha
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 02.02.2023
Nature Publishing Group
Nature Portfolio
Subjects
631/67/589/466
692/4028/67/589/466
Androgens
Cancer therapies
Castration
Comment
Deprivation
DNA methylation
Epigenesis, Genetic
Epigenetics
Gene expression
Genomes
Genotype & phenotype
Heterogeneity
Humanities and Social Sciences
Humans
Male
multidisciplinary
Mutation
Neoplasm Recurrence, Local - genetics
Neoplasm Recurrence, Local - pathology
Prostate cancer
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Proteins
Science
Science (multidisciplinary)
Transcription factors
Tumors
Online AccessGet full text

Cover

More Information
Summary:Prostate cancer is a highly heterogeneous disease. Progression on androgen deprivation therapy (ADT) to castration-resistant (CRPC), or neuroendocrine prostate cancer (NEPC), is associated with poor patient survival. This comment highlights recent evidence on the epigenetic mechanisms underlying the emergence of lineage plasticity and neuroendocrine differentiation in treatment-resistant prostate tumors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-023-36253-1